Capital International Inc. CA Boosts Stock Holdings in Illumina, Inc. $ILMN

Key Points

• Capital International Inc. CA boosted its stake by 52.3% in Illumina during Q3, adding 29,935 shares to hold 87,136 shares worth about $8.28 million (≈0.06% of the company) per its latest 13F filing.
• Illumina beat quarterly estimates with $1.35 EPS (vs. $1.26) and $1.16 billion in revenue (vs. $1.10B), and issued FY2026 guidance of 5.05–5.20 EPS.
• Several analysts raised price targets (e.g., Guggenheim to $170, Stifel to $155) but consensus remains a Hold with an average target price of $129.69.

Capital International Inc. CA raised its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 52.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 87,136 shares of the life sciences company's stock after acquiring an additional 29,935 shares during the period. Capital International Inc. CA owned approximately 0.06% of Illumina worth $8,275,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Empowered Funds LLC grew its position in Illumina by 113.7% in the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company's stock worth $737,000 after acquiring an additional 4,940 shares in the last quarter. Sivia Capital Partners LLC purchased a new stake in Illumina during the second quarter valued at approximately $621,000. AE Wealth Management LLC raised its position in Illumina by 5.8% during the second quarter. AE Wealth Management LLC now owns 30,381 shares of the life sciences company's stock valued at $2,899,000 after purchasing an additional 1,664 shares during the period. Aviva PLC lifted its stake in shares of Illumina by 7.0% in the 2nd quarter. Aviva PLC now owns 116,925 shares of the life sciences company's stock valued at $11,156,000 after purchasing an additional 7,609 shares during the last quarter. Finally, Parkside Financial Bank & Trust lifted its stake in shares of Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company's stock valued at $28,000 after purchasing an additional 115 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Stifel Nicolaus boosted their target price on Illumina from $135.00 to $155.00 and gave the company a "buy" rating in a research report on Tuesday, January 20th. Guggenheim raised their price target on Illumina from $144.00 to $170.00 and gave the stock a "buy" rating in a research report on Monday, January 26th. Barclays lifted their price objective on shares of Illumina from $100.00 to $110.00 and gave the stock an "underweight" rating in a research note on Monday, December 15th. Evercore set a $150.00 price objective on shares of Illumina in a research report on Friday, February 6th. Finally, Zacks Research downgraded shares of Illumina from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, December 31st. Six analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $129.69.

Illumina Stock Performance

Shares of Illumina stock opened at $122.35 on Wednesday. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55. The stock's fifty day moving average price is $133.96 and its 200-day moving average price is $119.69. The firm has a market cap of $18.71 billion, a P/E ratio of 22.45, a P/E/G ratio of 2.38 and a beta of 1.45. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $155.53.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.09. The company had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The firm's quarterly revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, equities research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Scott M. Davies sold 323 shares of the stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the transaction, the insider directly owned 17,887 shares in the company, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the transaction, the senior vice president directly owned 16,321 shares in the company, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.17% of the stock is currently owned by company insiders.

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.